Professor of Medicine, Massachusetts General Hospital
Hematology
Dr. David J. Kuter, MD
|
|
Give Review
David J. Kuter practices Hematology. He graduated from Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He over the years received 2 awards: "Super Doctor" and "Top MD". Dr. David J. Kuter is also published. He has 98 publications published. The lastest publication: "The protein composition of HeLa ribosomal subunits and nucleolar precursor particles.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Treatment patterns and clinical outcomes in patients with Chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
- TPO concentrations and response to romiplostim.
- A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and Chronic immune thrombocytopenia.
- Milestones in understanding platelet production: a historical overview.
- Rituximab therapy for factor II inhibitor in a patient with Antiphospholipid antibody syndrome.
- Thrombopoietin (TPO) levels in patients with Disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists.
- Redo aortic valve replacement in a patient with immunoglobulin A deficiency and Hemophilia A.
- The biology of thrombopoietin and thrombopoietin receptor agonists.
- Miglustat therapy in type 1 Gaucher Disease: Clinical and safety outcomes in a multicenter retrospective cohort study.
- Long-term treatment with romiplostim in patients with Chronic immune thrombocytopenia: safety and efficacy.
- Neutrophil-erythrocyte rosettes in autoimmune hemolytic Anemia.
- Health-related quality of life in nonsplenectomized Immune thrombocytopenia patients receiving romiplostim or medical standard of care.
- Myeloid growth factors.
- Gastrointestinal disturbances and their management in miglustat-treated patients.
- Abdominal Contouring Procedures Increase Activity of the Coagulation Cascade.
- Romiplostim.
- Romiplostim or standard of care in patients with Immune thrombocytopenia.
- Massive hepatomegaly and involvement by Janus Kinase 2-positive Myeloproliferative neoplasm.
- Serum free light chain analysis.
- What do healthcare providers ask their patients with Immune thrombocytopenia?
- Biology and chemistry of thrombopoietic agents.
- New thrombopoietic agents: introduction.
- International consensus report on the investigation and management of primary Immune thrombocytopenia.
- Practice guidelines often fail to keep pace with the rapid evolution of medicine: a call for clinicians to remain vigilant and revisit their own practice patterns.
- Thrombopoietin and platelet production in Chronic immune thrombocytopenia.
- Evaluation of bone marrow reticulin formation in Chronic immune thrombocytopenia patients treated with romiplostim.
- Single-agent bortezomib in previously untreated multiple Myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neu...
- Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with Chronic ITP.
- ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13.
- New thrombopoietic growth factors.
- Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
- Successful treatment of pure red cell aplasia with autologous stem cell transplantation.
- Dalteparin-induced skin necrosis in a patient with metastatic Lung adenocarcinoma.
- AMG 531, a thrombopoiesis-stimulating protein, for Chronic ITP.
- Successful recovery after an overdose of argatroban.
- Effects of biochemically confirmed smoking cessation on white blood cell count.
- The promise of thrombopoietins in the treatment of ITP.
- Catheter-related thrombosis in Cancer patients: pathophysiology, diagnosis, and management.
- Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid-AM on the survival and function...
- Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.
- Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.
- Hematologic effects of linezolid: summary of clinical experience.
- Whatever happened to thrombopoietin?
- Cancer, coagulation, and anticoagulation.
- Apoptosis in transfusion medicine: of death and dying--is that all there is?
- Future directions with platelet growth factors.
- Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets.
- Thrombopoietin and the TPO receptorduring platelet storage.
- Cover art: the watercolor drawings of James Homer Wright.
- Trombopoietin: from molecule to medicine. Preface.
- The use of PEG-rhuMGDF in platelet apheresis.
- The physiology of platelet production.
- The mechanism of apoptosis in human platelets during storage.
- The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia.
- A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
- Postmarketing surveillance of new food ingredients: results from the program with the fat replacer olestra.
- The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
- Thrombopoietin therapy increases platelet yields in healthy platelet donors.
- Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
- Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid.
- Thrombocytopenia caused by the development of antibodies to thrombopoietin.
- The end is just the beginning: megakaryocyte apoptosis and platelet release.
- What is the potential for thrombopoietic agents in Acute leukemia?
- Dabigatran: a review of clinical and pharmacoeconomic evidence.
- The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance.
- Linear free energy relationships predict coordination and ?-stacking interactions of small molecules with ferriprotoporphyrin IX.
- Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols.
- A phase 2 study of bortezomib in relapsed, refractory Myeloma.
- Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues.
- Identification of del(20q) in a subset of patients diagnosed with idiopathic Thrombocytopenic purpura.
- What is the role for antithrombotics in Cancer care? Interactive session with panel discussion.
- Apoptosis in platelets during ex vivo storage.
- Apoptotic markers are increased in platelets stored at 37 degrees C.
- IgG antibodies against bovine serum albumin in humans--their prevalence and response to exposure to bovine serum albumin.
- Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres.
- Meeting the treatment challenges of Chronic immune thrombocytopenic purpura.
- New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and Immune thrombocytopenic purpura.
- Efficacy of romiplostim in patients with Chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
- Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events an...
- Improving the management of hypertension in Kazakhstan: implications for improving clinical practice, patient behaviours and health outcomes.
- The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.
- The protein composition of HeLa ribosomal subunits and nucleolar precursor particles.
- Botrocetin agglutination of rat megakaryocytes: a rapid method for megakaryocyte isolation.
- Transforming growth factor beta inhibits megakaryocyte growth and endomitosis.
- Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site.
- Platelets contain seVeral inhibitors of megakaryocyte growth and ploidization.
- Regulation of megakaryocyte ploidy in vivo in the rat.
- Analysis of megakaryocyte ploidy in rat bone marrow cultures.
- Elevated partial thromboplastin time as an indicator of hemorrhagic risk in postoperative patients on warfarin prophylaxis.
- In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor.
- Ribosomal protein differences between animal cells.
- rmIL-6 stimulates the transcriptional activity of the rat PF4 gene.
- The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.
- The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.
- Appearance of a megakaryocyte growth-promoting activity, megapoietin, during Acute thrombocytopenia in the rabbit.
- Selection of an HEL-derived cell line expressing high levels of platelet factor 4.
- Thrombopoietin: biology, clinical applications, role in the donor setting.
Schools
Harvard Medical School
Massachusetts General Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
- Top MD
Education
-
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1457342024 | |
| NPPES Provider LastName | KUTER | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 02114 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 125.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457342024 |
| Last Name Of The Provider | KUTER |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Richard T. Penson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar M. Castro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey Liu, MD |
|
|
Dr. Yoo-Joung Ko, MD |
|
|
Dr. Pavan Bachireddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maureen M. Okam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan E. Rosenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jochen H. Lorch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Parul Bhargava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Rabin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert I. Handin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonard L. Ellman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah M. Scott, MD |
|
|
Dr. Jill N. Allen, MD |
|
|
Dr. Rita A. Blanchard, MD
This Doctor is OpenDoctor Recommended.
|